Complication rates of 3% hypertonic saline infusion through peripheral intravenous access

Claudia Andira Perez, Stephen A. Figueroa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Hyperosmolar therapy with hypertonic saline (HTS) is a cornerstone in the management of intracranial hypertension and hyponatremia in the neurological intensive care unit. Theoretical safety concerns remain for infiltration, thrombophlebitis, tissue ischemia, and venous thrombosis associated with continuous 3% HTS administered via peripheral intravenous (pIV) catheters. It is common practice at many institutions to allow only central venous catheter infusion of 3% HTS. Methods: Hospital policy was changed to allow the administration of 3% HTS via 16-to 20-gauge pIVs to a maximum infusion rate of 50 mL/h in patients without central venous access. We prospectively monitored patients who received peripheral 3% HTS as part of a quality improvement project. We documented gauge, location, maximum infusion rate, and total hours of administration. Patients were assessed for infiltration, erythema, swelling, phlebitis, thrombosis, and line infection. Results: There were 28 subjects across 34 peripheral lines monitored. Overall, subjects received 3% HTS for a duration between 1 and 124 hours with infusion rates of 30 to 50 mL/h. The rate of complications observed was 10.7% among all subjects. Documented complications included infiltration (n = 2), with an incidence of 6%, and thrombophlebitis (n = 1), with an incidence of 3%. Conclusions: There has been a long concern among healthcare providers, including nursing staff, in regard to pIV administration of prolonged 3% HTS infusion therapy. Our study indicates that peripheral administration of 3% HTS carries a low risk of minor, nonlimb, or life-threatening complications. Although central venous infusion may reduce the risk of these minor complications, it may increase the risk of more serious complications such as large vessel thrombosis, bloodstream infection, pneumothorax, and arterial injury. The concern regarding the risks of pIV administration of 3% HTS may be overstated and unfounded.

Original languageEnglish (US)
Pages (from-to)191-195
Number of pages5
JournalJournal of Neuroscience Nursing
Volume49
Issue number3
DOIs
StatePublished - 2017

Fingerprint

Thrombophlebitis
Intravenous Administration
Thrombosis
Phlebitis
Intracranial Hypertension
Central Venous Catheters
Hyponatremia
Nursing Staff
Incidence
Pneumothorax
Erythema
Quality Improvement
Infection
Venous Thrombosis
Health Personnel
Intensive Care Units
Ischemia
Catheters
Safety
Wounds and Injuries

Keywords

  • Intracranial hemorrhage
  • Neurocritical care
  • Neuropharmacology
  • Safety
  • Subarachnoid hemorrhage

ASJC Scopus subject areas

  • Surgery
  • Endocrine and Autonomic Systems
  • Clinical Neurology
  • Medical–Surgical

Cite this

Complication rates of 3% hypertonic saline infusion through peripheral intravenous access. / Perez, Claudia Andira; Figueroa, Stephen A.

In: Journal of Neuroscience Nursing, Vol. 49, No. 3, 2017, p. 191-195.

Research output: Contribution to journalArticle

@article{4de34b9a51584bb89eb922ebe72a3034,
title = "Complication rates of 3{\%} hypertonic saline infusion through peripheral intravenous access",
abstract = "Introduction: Hyperosmolar therapy with hypertonic saline (HTS) is a cornerstone in the management of intracranial hypertension and hyponatremia in the neurological intensive care unit. Theoretical safety concerns remain for infiltration, thrombophlebitis, tissue ischemia, and venous thrombosis associated with continuous 3{\%} HTS administered via peripheral intravenous (pIV) catheters. It is common practice at many institutions to allow only central venous catheter infusion of 3{\%} HTS. Methods: Hospital policy was changed to allow the administration of 3{\%} HTS via 16-to 20-gauge pIVs to a maximum infusion rate of 50 mL/h in patients without central venous access. We prospectively monitored patients who received peripheral 3{\%} HTS as part of a quality improvement project. We documented gauge, location, maximum infusion rate, and total hours of administration. Patients were assessed for infiltration, erythema, swelling, phlebitis, thrombosis, and line infection. Results: There were 28 subjects across 34 peripheral lines monitored. Overall, subjects received 3{\%} HTS for a duration between 1 and 124 hours with infusion rates of 30 to 50 mL/h. The rate of complications observed was 10.7{\%} among all subjects. Documented complications included infiltration (n = 2), with an incidence of 6{\%}, and thrombophlebitis (n = 1), with an incidence of 3{\%}. Conclusions: There has been a long concern among healthcare providers, including nursing staff, in regard to pIV administration of prolonged 3{\%} HTS infusion therapy. Our study indicates that peripheral administration of 3{\%} HTS carries a low risk of minor, nonlimb, or life-threatening complications. Although central venous infusion may reduce the risk of these minor complications, it may increase the risk of more serious complications such as large vessel thrombosis, bloodstream infection, pneumothorax, and arterial injury. The concern regarding the risks of pIV administration of 3{\%} HTS may be overstated and unfounded.",
keywords = "Intracranial hemorrhage, Neurocritical care, Neuropharmacology, Safety, Subarachnoid hemorrhage",
author = "Perez, {Claudia Andira} and Figueroa, {Stephen A.}",
year = "2017",
doi = "10.1097/JNN.0000000000000286",
language = "English (US)",
volume = "49",
pages = "191--195",
journal = "Journal of Neuroscience Nursing",
issn = "0888-0395",
publisher = "American Association of Neuroscience Nurses",
number = "3",

}

TY - JOUR

T1 - Complication rates of 3% hypertonic saline infusion through peripheral intravenous access

AU - Perez, Claudia Andira

AU - Figueroa, Stephen A.

PY - 2017

Y1 - 2017

N2 - Introduction: Hyperosmolar therapy with hypertonic saline (HTS) is a cornerstone in the management of intracranial hypertension and hyponatremia in the neurological intensive care unit. Theoretical safety concerns remain for infiltration, thrombophlebitis, tissue ischemia, and venous thrombosis associated with continuous 3% HTS administered via peripheral intravenous (pIV) catheters. It is common practice at many institutions to allow only central venous catheter infusion of 3% HTS. Methods: Hospital policy was changed to allow the administration of 3% HTS via 16-to 20-gauge pIVs to a maximum infusion rate of 50 mL/h in patients without central venous access. We prospectively monitored patients who received peripheral 3% HTS as part of a quality improvement project. We documented gauge, location, maximum infusion rate, and total hours of administration. Patients were assessed for infiltration, erythema, swelling, phlebitis, thrombosis, and line infection. Results: There were 28 subjects across 34 peripheral lines monitored. Overall, subjects received 3% HTS for a duration between 1 and 124 hours with infusion rates of 30 to 50 mL/h. The rate of complications observed was 10.7% among all subjects. Documented complications included infiltration (n = 2), with an incidence of 6%, and thrombophlebitis (n = 1), with an incidence of 3%. Conclusions: There has been a long concern among healthcare providers, including nursing staff, in regard to pIV administration of prolonged 3% HTS infusion therapy. Our study indicates that peripheral administration of 3% HTS carries a low risk of minor, nonlimb, or life-threatening complications. Although central venous infusion may reduce the risk of these minor complications, it may increase the risk of more serious complications such as large vessel thrombosis, bloodstream infection, pneumothorax, and arterial injury. The concern regarding the risks of pIV administration of 3% HTS may be overstated and unfounded.

AB - Introduction: Hyperosmolar therapy with hypertonic saline (HTS) is a cornerstone in the management of intracranial hypertension and hyponatremia in the neurological intensive care unit. Theoretical safety concerns remain for infiltration, thrombophlebitis, tissue ischemia, and venous thrombosis associated with continuous 3% HTS administered via peripheral intravenous (pIV) catheters. It is common practice at many institutions to allow only central venous catheter infusion of 3% HTS. Methods: Hospital policy was changed to allow the administration of 3% HTS via 16-to 20-gauge pIVs to a maximum infusion rate of 50 mL/h in patients without central venous access. We prospectively monitored patients who received peripheral 3% HTS as part of a quality improvement project. We documented gauge, location, maximum infusion rate, and total hours of administration. Patients were assessed for infiltration, erythema, swelling, phlebitis, thrombosis, and line infection. Results: There were 28 subjects across 34 peripheral lines monitored. Overall, subjects received 3% HTS for a duration between 1 and 124 hours with infusion rates of 30 to 50 mL/h. The rate of complications observed was 10.7% among all subjects. Documented complications included infiltration (n = 2), with an incidence of 6%, and thrombophlebitis (n = 1), with an incidence of 3%. Conclusions: There has been a long concern among healthcare providers, including nursing staff, in regard to pIV administration of prolonged 3% HTS infusion therapy. Our study indicates that peripheral administration of 3% HTS carries a low risk of minor, nonlimb, or life-threatening complications. Although central venous infusion may reduce the risk of these minor complications, it may increase the risk of more serious complications such as large vessel thrombosis, bloodstream infection, pneumothorax, and arterial injury. The concern regarding the risks of pIV administration of 3% HTS may be overstated and unfounded.

KW - Intracranial hemorrhage

KW - Neurocritical care

KW - Neuropharmacology

KW - Safety

KW - Subarachnoid hemorrhage

UR - http://www.scopus.com/inward/record.url?scp=85020303585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020303585&partnerID=8YFLogxK

U2 - 10.1097/JNN.0000000000000286

DO - 10.1097/JNN.0000000000000286

M3 - Article

C2 - 28471928

AN - SCOPUS:85020303585

VL - 49

SP - 191

EP - 195

JO - Journal of Neuroscience Nursing

JF - Journal of Neuroscience Nursing

SN - 0888-0395

IS - 3

ER -